Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
Titel:
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
Auteur:
Musacchio, Lucia Salutari, Vanda Pignata, Sandro Braicu, Elena Cibula, David Colombo, Nicoletta Frenel, Jean Sebastien Zagouri, Flora Carbone, Vittoria Ghizzoni, Viola Giolitto, Serena Giudice, Elena Te Perri, Maria resa Ricci, Caterina Scambia, Giovanni Lorusso, Domenica
Verschenen in:
International journal of gynecological cancer
Paginering:
Jaargang 31 () nr. 10 pagina's 1369-1373
Jaar:
2021
Inhoud:
Uitgever:
IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.